<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9775">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05690464</url>
  </required_header>
  <id_info>
    <org_study_id>2022P002101</org_study_id>
    <nct_id>NCT05690464</nct_id>
  </id_info>
  <brief_title>Effect of Magnesium Supplementation on Elevated Systolic Blood Pressure</brief_title>
  <official_title>Trial of Magnesium Supplementation and Blood Pressure Reduction Among Adults With Elevated Systolic Blood Pressure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pure Encapsulations</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether 480 mg/day magnesium glycinate supplementation&#xD;
      for 12 weeks lowers blood pressure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial will test whether a magnesium glycinate supplement (480 mg/day) taken for&#xD;
      12 weeks lowers blood pressure in 120 adults aged 30-74 who have a systolic blood pressure of&#xD;
      130-154 mmHg and are not taking anti-hypertensive medications.&#xD;
&#xD;
      Eligibility to participate in the trial will be determined by a 2-stage screening process.&#xD;
      Interested participants will complete a pre-screening form online. If eligibility criteria&#xD;
      are met, the potential participants will be scheduled for an in-person screening clinic&#xD;
      visit. At the visit, eligible participants will be reminded about the study details and&#xD;
      potential risks and will be given the opportunity to sign the Informed Consent. Consented&#xD;
      participants will be assigned by chance (like a coin toss) to daily magnesium or to placebo.&#xD;
      Participants will take 4 study capsules per day (2 capsules in the morning and 2 capsules in&#xD;
      the evening) for 12 weeks.&#xD;
&#xD;
      Assessments at the screening visit include seated blood pressure; pulse; weight, height,&#xD;
      waist and hip circumference measurements; fasting blood and urine collection; and health and&#xD;
      diet questionnaires. Participants will return for a clinic visit at 12 weeks to assess these&#xD;
      measures.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 17, 2023</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in seated systolic blood pressure from baseline to 12 weeks</measure>
    <time_frame>Baseline and 12 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in seated diastolic blood pressure from baseline to 12 weeks</measure>
    <time_frame>Baseline and 12 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum magnesium levels from baseline to 12 weeks</measure>
    <time_frame>Baseline and 12 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in RBC magnesium levels from baseline to 12 weeks</measure>
    <time_frame>Baseline and 12 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whether the effect of magnesium on seated blood pressure is modified by baseline serum and/or RBC magnesium</measure>
    <time_frame>Baseline and 12 week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Blood Pressure</condition>
  <arm_group>
    <arm_group_label>magnesium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>magnesium glycinate supplement, 480 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo supplement</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>magnesium glycinate supplement</intervention_name>
    <description>magnesium glycinate (480 mg/day)</description>
    <arm_group_label>magnesium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Self-report of systolic blood pressure 125-139 mmHg&#xD;
&#xD;
          -  Measured seated systolic blood pressure 130-154 mmHg at screening visit&#xD;
&#xD;
          -  Body mass index less than 40 kg/m2&#xD;
&#xD;
          -  Total magnesium intake from supplements of no more than 100 mg/day&#xD;
&#xD;
          -  Willing to maintain current diet and supplement use patterns during the 12-week&#xD;
             intervention period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or past history of anti-hypertensive medication use&#xD;
&#xD;
          -  Measured seated diastolic blood pressure 100 mmHg or greater at screening visit&#xD;
&#xD;
          -  Antacid or laxative use 4 times/week or more within the past 3 months&#xD;
&#xD;
          -  History of cardiovascular disease (myocardial infarction, stroke, revascularization&#xD;
             [coronary artery bypass graft or percutaneous transluminal coronary angioplasty], or&#xD;
             angina pectoris)&#xD;
&#xD;
          -  History of invasive cancer diagnosed within the last 5 years (non-melanoma skin cancer&#xD;
             permitted)&#xD;
&#xD;
          -  History of type 1 or 2 diabetes&#xD;
&#xD;
          -  History of renal disease&#xD;
&#xD;
          -  History of kidney failure&#xD;
&#xD;
          -  History of dialysis&#xD;
&#xD;
          -  History of pancreatitis&#xD;
&#xD;
          -  History of inflammatory bowel disease&#xD;
&#xD;
          -  History of hypermagnesemia&#xD;
&#xD;
          -  Women who are pregnant, nursing, or intend to become pregnant during the period of&#xD;
             treatment&#xD;
&#xD;
          -  Plan to relocate out of Boston area within the next year&#xD;
&#xD;
          -  Unwillingness and/or inability to swallow 4 pills per day&#xD;
&#xD;
          -  Inability to provide written informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Howard Sesso, ScD, MPH</last_name>
    <phone>617-278-0803</phone>
    <email>hsesso@bwh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Trisha Copeland, MS, RD</last_name>
    <phone>617-278-0803</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Copeland, MS, RD</last_name>
      <phone>617-278-0803</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>January 10, 2023</study_first_submitted>
  <study_first_submitted_qc>January 10, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2023</study_first_posted>
  <last_update_submitted>February 1, 2023</last_update_submitted>
  <last_update_submitted_qc>February 1, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Howard D. Sesso, ScD, MPH</investigator_full_name>
    <investigator_title>Associate Epidemiologist, Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Systolic Murmurs</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

